2082631-84-1
Chemical Structure
Ricorfotide vedotin
Synonym(s): CBP-1008; LDC 10B
- CAS No.: 2082631-84-1
- Formula:C162H243N39O40S
- Molecular Weight:3408.97
InChIKey: YGUQMOLGQZUHPI-POCOVCJGSA-N
SMILES: O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN4C(C(CC4=O)SC[C@H](NC(CC[C@@H](C(O)=O)NC(C5=CC=C(C=C5)NCC(N=C67)=CNC6=NC(N)=NC7=O)=O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC8=CN=CN8)C(N9[C@@H](CCC9)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N%10[C@@H](CCC%10)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC%11=CC=CC=C%11)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)OC)=O
Biological Activity: Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ricorfotide vedotin | 98.45% | Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fu, et al. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta pharmaceutica Sinica. B. 2023, 13(2), 498–516. [Content Brief]
- [2]. Gong, et al. First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors. Journal of Clinical Oncology. 2023, 41 (16).
- [3]. Tan, et al. CBP-1008 shows excellent efficacy and desirable drug safety profile in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2022. 2022, 82(12_Suppl).
